Latest & greatest articles for alendronate

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on alendronate or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on alendronate and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for alendronate

21. Alendronate sodium / cholecalciferol - Osteoporosis

Alendronate sodium / cholecalciferol - Osteoporosis Common Drug Review CEDAC Meeting – May 20, 2009 Page 1 of 2 Notice of CEDAC Final Recommendation – June 17, 2009 © 2009 CADTH CEDAC FINAL RECOMMENDATION and REASONS for RECOMMENDATION ALENDRONATE/CHOLECALCIFEROL (Fosavance ® 70/5600 – Merck Frosst Canada Ltd.) Indication: Osteoporosis Description: Fosavance 70/5600 is a fixed dose combination of alendronate, a bisphosphonate that inhibits bone resorption, and cholecalciferol (vitamin D 3 (...) ). Fosavance 70/5600 is approved by Health Canada for the treatment of osteoporosis in men and postmenopausal women. CEDAC previously reviewed Fosavance (referred to as Fosavance 70/2800 in this document), which contains alendronate 70 mg and 70 µg cholecalciferol, and recommended that it not be listed (see Fosavance Notice of CEDAC Final Recommendation on September 27, 2006). Dosage Forms: Supplied as tablets containing alendronate 70 mg and cholecalciferol 140 µg (5600 IU vitamin D 3 ). The recommended

2009 Canadian Agency for Drugs and Technologies in Health - Common Drug Review

22. Clinical trial: comparison of alendronate and alfacalcidol in glucocorticoid-associated osteoporosis in patients with ulcerative colitis (PubMed)

Clinical trial: comparison of alendronate and alfacalcidol in glucocorticoid-associated osteoporosis in patients with ulcerative colitis Bone loss is often observed in patients with ulcerative colitis, particularly if they require glucocorticoids.To determine whether the bisphosphonate, alendronate, is safe and effective in preserving bone mass compared to the active vitamin D3, alfacalcidol, in ulcerative colitis patients receiving glucocorticoids.Thirty-nine patients with ulcerative colitis (...) and treated with glucocorticoids were randomized to receive alendronate (5 mg/day) or alfacalcidol (1 microg/day) daily for 12 months. Loss of bone mass was evaluated by bone mineral density, bone resorption by urinary N-telopeptide for type I collagen, and bone formation by serum bone alkaline phosphatase.Alendronate, but not alfacalcidol, significantly increased bone mineral density in the lumbar spine. Alendronate decreased serum bone alkaline phosphatase levels, but alfacalcidol did not. Urinary N

Full Text available with Trip Pro

2009 EvidenceUpdates

23. Alendronate Once Weekly for the Prevention and Treatment of Bone Loss in Canadian Adult Cystic Fibrosis Patients (CFOS Trial) (PubMed)

Alendronate Once Weekly for the Prevention and Treatment of Bone Loss in Canadian Adult Cystic Fibrosis Patients (CFOS Trial) Patients with cystic fibrosis (CF) are at risk for early bone loss, and demonstrate increased risks for vertebral fractures and kyphosis. A multicenter, randomized, controlled trial was conducted to assess the efficacy, tolerability, and safety of therapy with oral alendronate (FOSAMAX; Merck; Whitehouse Station, NJ) in adults with CF and low bone mass.Participants (...) received placebo or alendronate, 70 mg once weekly, for 12 months. All participants received 800 IU of vitamin D and 1,000 mg of calcium daily. Adults with confirmed CF with a bone mineral density (BMD) T score of < - 1.0 were eligible for inclusion. Participants who had undergone organ transplantation or had other reported contraindications were excluded from the study. The primary outcome measure was the mean (+/- SD) percentage change in lumbar spine BMD after 12 months. Secondary measures included

Full Text available with Trip Pro

2008 EvidenceUpdates

24. Skeletal health after continuation, withdrawal, or delay of alendronate in men with prostate cancer undergoing androgen-deprivation therapy (PubMed)

Skeletal health after continuation, withdrawal, or delay of alendronate in men with prostate cancer undergoing androgen-deprivation therapy Androgen-deprivation therapy (ADT) for prostate cancer is associated with bone loss and osteoporotic fractures. Our objective was to examine changes in bone density and turnover with sustained, discontinued, or delayed oral bisphosphonate therapy in men receiving ADT.A total of 112 men with nonmetastatic prostate cancer receiving ADT were randomly assigned (...) to alendronate 70 mg once weekly or placebo in a double-blind, partial-crossover trial with a second random assignment at year 2 for those who initially received active therapy. Outcomes included bone mineral density and bone turnover markers.Men initially randomly assigned to alendronate and randomly reassigned at year 2 to continue had additional bone density gains at the spine (mean, 2.3% +/- 0.7) and hip (mean, 1.3% +/- 0.5%; both P < .01); those randomly assigned to placebo in year 2 maintained density

Full Text available with Trip Pro

2008 EvidenceUpdates

25. Continuing alendronate for an additional 5 years maintained bone mineral density in postmenopausal women

Continuing alendronate for an additional 5 years maintained bone mineral density in postmenopausal women Continuing alendronate for an additional 5 years maintained bone mineral density in postmenopausal women | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password (...) For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Continuing alendronate for an additional 5 years maintained bone mineral density in postmenopausal women Article Text Therapeutics Continuing alendronate for an additional 5 years

2008 Evidence-Based Medicine (Requires free registration)

26. A comparison of the effect of alendronate and risedronate on bone mineral density in postmenopausal women with osteoporosis: 24-month results from FACTS-International (PubMed)

A comparison of the effect of alendronate and risedronate on bone mineral density in postmenopausal women with osteoporosis: 24-month results from FACTS-International To compare alendronate 70 mg once weekly (OW) with risedronate 35 mg OW with respect to change in bone mineral density (BMD), biochemical markers and upper gastrointestinal (UGI) tolerability over 24 months.This was a 12-month extension to the Fosamax Actonel Comparison Trial international study (FACTS). Postmenopausal women (...) with osteoporosis randomly assigned to either alendronate 70 mg OW or risedronate 35 mg OW for the 12-month base study continued taking the same double-blind study medication. Efficacy measurements were BMD at the hip trochanter, lumbar spine, total hip, and femoral neck and levels of four bone turnover markers at 24 months. The primary hypothesis was that alendronate would produce a greater mean per cent increase from baseline in hip trochanter BMD at 24 months.Trochanter BMD increased significantly from

2008 EvidenceUpdates

27. Cost-effectiveness of a fixed dose combination of alendronate and cholecalciferol in the treatment and prevention of osteoporosis in the United Kingdom and The Netherlands

Cost-effectiveness of a fixed dose combination of alendronate and cholecalciferol in the treatment and prevention of osteoporosis in the United Kingdom and The Netherlands Cost-effectiveness of a fixed dose combination of alendronate and cholecalciferol in the treatment and prevention of osteoporosis in the United Kingdom and The Netherlands Cost-effectiveness of a fixed dose combination of alendronate and cholecalciferol in the treatment and prevention of osteoporosis in the United Kingdom (...) that the alendronate vitamin D3 combination was cost-effective in women aged 70 years or older with osteoporosis, and in women aged 60 years or older with a history of vertebral fracture. The methodology was appropriate and the methods used and the results were appropriately reported. The authors' conclusions appear to be appropriate given the scope of the study. Type of economic evaluation Cost-utility analysis Study objective The objective was to evaluate the cost-effectiveness of a fixed dose combination

2008 NHS Economic Evaluation Database.

28. Alendronate prevents osteoporotic fractures in at risk postmenopausal women

Alendronate prevents osteoporotic fractures in at risk postmenopausal women PEARLS Practical Evidence About Real Life Situations PEARLS are succinct summaries of Cochrane Systematic Reviews for primary care practitioners. They are funded by the New Zealand Guidelines Group. PEARLS provide guidance on whether a treatment is effective or ineffective. PEARLS are prepared as an educational resource and do not replace clinician judgement in the management of individual cases. View PEARLS online (...) at: www.cochraneprimarycare.org Alendronate prevents osteoporotic fractures in at risk postmenopausal women Clinical question How effective is alendronate in the primary and secondary prevention of osteoporotic fractures in postmenopausal women? Bottom line At an alendronate dose of 10 mg per day, both clinically important and statistically significant reductions in vertebral (NNT*16), non-vertebral (NNT 50), hip (NNT 100) and wrist (NNT 50) fractures were observed for secondary prevention but there were no significant

2008 Cochrane PEARLS

29. Greater first year effectiveness drives favorable cost-effectiveness of brand risedronate versus generic or brand alendronate: modeled Canadian analysis

Greater first year effectiveness drives favorable cost-effectiveness of brand risedronate versus generic or brand alendronate: modeled Canadian analysis Greater first year effectiveness drives favorable cost-effectiveness of brand risedronate versus generic or brand alendronate: modeled Canadian analysis Greater first year effectiveness drives favorable cost-effectiveness of brand risedronate versus generic or brand alendronate: modeled Canadian analysis Grima D T, Papaioannou A, Thompson M F (...) , Pasquale M K, Adachi J D Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study assessed the cost-effectiveness of risedronate in comparison with generic or brand alendronate, for the treatment of osteoporotic women, aged 65 years

Full Text available with Trip Pro

2008 NHS Economic Evaluation Database.

30. Alendronate, etidronate, risedronate, raloxifene, strontium ranelate and teriparatide for the&#160

Alendronate, etidronate, risedronate, raloxifene, strontium ranelate and teriparatide for the  Overview | Raloxifene and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women | Guidance | NICE Raloxifene and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women Technology appraisal guidance [TA161] Published date: 27 October 2008 Last updated: 07 February 2018 Share Save Guidance on raloxifene

2008 National Institute for Health and Clinical Excellence - Technology Appraisals

31. Alendronate, etidronate, risedronate, raloxifene and strontium ranelate for the primary prevention of osteoporotic fragility fractures in postmenopausal women (amended) (TA160)

Alendronate, etidronate, risedronate, raloxifene and strontium ranelate for the primary prevention of osteoporotic fragility fractures in postmenopausal women (amended) (TA160) Overview | Raloxifene for the primary prevention of osteoporotic fragility fractures in postmenopausal women | Guidance | NICE Raloxifene for the primary prevention of osteoporotic fragility fractures in postmenopausal women Technology appraisal guidance [TA160] Published date: 27 October 2008 Last updated: 07 February

2008 National Institute for Health and Clinical Excellence - Technology Appraisals

32. Teriparatide or alendronate in glucocorticoid-induced osteoporosis. (PubMed)

Teriparatide or alendronate in glucocorticoid-induced osteoporosis. Bisphosphonate therapy is the current standard of care for the prevention and treatment of glucocorticoid-induced osteoporosis. Studies of anabolic therapy in patients who are receiving long-term glucocorticoids and are at high risk for fracture are lacking.In an 18-month randomized, double-blind, controlled trial, we compared teriparatide with alendronate in 428 women and men with osteoporosis (ages, 22 to 89 years) who had (...) received glucocorticoids for at least 3 months (prednisone equivalent, 5 mg daily or more). A total of 214 patients received 20 microg of teriparatide once daily, and 214 received 10 mg of alendronate once daily. The primary outcome was the change in bone mineral density at the lumbar spine. Secondary outcomes included changes in bone mineral density at the total hip and in markers of bone turnover, the time to changes in bone mineral density, the incidence of fractures, and safety.At the last

2007 NEJM

33. Simulation-based cost-utility analysis of population screening-based alendronate use in Switzerland

Simulation-based cost-utility analysis of population screening-based alendronate use in Switzerland Simulation-based cost-utility analysis of population screening-based alendronate use in Switzerland Simulation-based cost-utility analysis of population screening-based alendronate use in Switzerland Schwenkglenks M, Lippuner K Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods (...) , the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The study compared population-based dual-energy X-ray absorptiometry (DXA) screening followed by treatment with alendronate (FOSAMAX; Merck & Co) versus no screening or drug treatment for osteopenia and osteoporosis. The main screening ages were 65, 75 and 85 years. The three treatment options compared were treatment with alendronate for 5 years with full

Full Text available with Trip Pro

2007 NHS Economic Evaluation Database.

34. Adrovance (alendronate sodium trihydrate / colecalciferol)

Adrovance (alendronate sodium trihydrate / colecalciferol) EMEA 2007 1/2 SCIENTIFIC DISCUSSION 1. Introduction This application has been submitted as an informed consent application in accordance with Article 10c of Directive 2001/83/EC, as amended. Therefore, consent from the MAH of the FOSAVANCE application, which had been submitted as a full application under Art 8(3) of Directive 2001/83/EC as amended, has been given allowing access to Module 2 to Module 5 of the initial dossier (...) in the product information. However, the applicant is asked to provide an updated Risk Management Plan taken into account the comments raised during the assessment, at the time of the first PSUR. 6. Overall conclusions, risk/benefit assessment and recommendation Since this application is an informed consent of the FOSAVANCE application, the CHMP considered that the risk-benefit balance of ADROVANCE (70 mg alendronic acid as alendronate sodium trihydrate and /70 micrograms colecalciferol) tablet given once

2007 European Medicines Agency - EPARs

35. Alendronate sodium/cholecalciferol

Alendronate sodium/cholecalciferol Common Drug Review CEDAC Meeting – July 26, 2006; CEDAC Reconsideration – September 20, 2006 Page 1 of 2 Notice of CEDAC Final Recommendation – September 27, 2006 CEDAC FINAL RECOMMENDATION on RECONSIDERATION and REASONS for RECOMMENDATION ALENDRONATE/CHOLECALCIFEROL (Fosavance ™ – Merck Frosst Canada Ltd.) Description: Fosavance ™ is a fixed dose combination of alendronate, a bisphosphonate that inhibits bone resorption, and cholecalciferol (vitamin D 3 (...) ). Fosavance ™ is approved for the treatment of osteoporosis in men and postmenopausal women. Dosage Forms: Tablet containing alendronate 70 mg and cholecalciferol 70 µg (2800 IU vitamin D 3 ) to be taken once weekly. Recommendation: The Canadian Expert Drug Advisory Committee (CEDAC) recommends that Fosavance ™ not be listed. Reasons for the Recommendation: 1. The Committee considered the results of one randomized controlled trial (RCT) in 717 patients with osteoporosis which compared the fixed dose

2006 Canadian Agency for Drugs and Technologies in Health - Common Drug Review

36. Alendronate or alfacalcidol in glucocorticoid-induced osteoporosis. (PubMed)

Alendronate or alfacalcidol in glucocorticoid-induced osteoporosis. Treatment with glucocorticoids is associated with bone loss starting soon after therapy is initiated and an increased risk of fracture.We performed a randomized, double-placebo, double-blind clinical trial of 18 months' duration among patients with a rheumatic disease who were starting glucocorticoids at a daily dose that was equivalent to at least 7.5 mg of prednisone. A total of 201 patients were assigned to receive either (...) alendronate (10 mg) and a placebo capsule of alfacalcidol daily or alfacalcidol (1 microg) and a placebo tablet of alendronate daily. The primary outcome was the change in bone mineral density of the lumbar spine in 18 months; the secondary outcome was the incidence of morphometric vertebral deformities.A total of 100 patients received alendronate, and 101 received alfacalcidol; 163 patients completed the study. The bone mineral density of the lumbar spine increased by 2.1 percent in the alendronate group

Full Text available with Trip Pro

2006 NEJM

37. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. (PubMed)

Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. The optimal duration of treatment of women with postmenopausal osteoporosis is uncertain.To compare the effects of discontinuing alendronate treatment after 5 years vs continuing for 10 years.Randomized, double-blind trial conducted at 10 US clinical centers that participated in the Fracture Intervention Trial (FIT).One thousand ninety-nine (...) postmenopausal women who had been randomized to alendronate in FIT, with a mean of 5 years of prior alendronate treatment.Randomization to alendronate, 5 mg/d (n = 329) or 10 mg/d (n = 333), or placebo (n = 437) for 5 years (1998-2003).The primary outcome measure was total hip bone mineral density (BMD); secondary measures were BMD at other sites and biochemical markers of bone remodeling. An exploratory outcome measure was fracture incidence.Compared with continuing alendronate, switching to placebo for 5

Full Text available with Trip Pro

2006 JAMA

38. The cost-effectiveness of therapy with teriparatide and alendronate in women with severe osteoporosis

The cost-effectiveness of therapy with teriparatide and alendronate in women with severe osteoporosis The cost-effectiveness of therapy with teriparatide and alendronate in women with severe osteoporosis The cost-effectiveness of therapy with teriparatide and alendronate in women with severe osteoporosis Liu H, Michaud K, Nayak S, Karpf D B, Owens D K, Garber A M Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract (...) contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The study examined three treatment strategies for postmenopausal women with severe osteoporosis: usual care (UC) based on calcium or vitamin D plus 5 years of alendronate therapy (alendronate alone); UC plus 2 years of teriparatide therapy (teriparatide alone); and UC plus 2 years of teriparatide therapy followed

Full Text available with Trip Pro

2006 NHS Economic Evaluation Database.

39. Cost-effectiveness of vertebral fracture assessment to detect prevalent vertebral deformity and select postmenopausal women with a femoral neck T-score > -2.5 for alendronate therapy: a modeling study

Cost-effectiveness of vertebral fracture assessment to detect prevalent vertebral deformity and select postmenopausal women with a femoral neck T-score > -2.5 for alendronate therapy: a modeling study Cost-effectiveness of vertebral fracture assessment to detect prevalent vertebral deformity and select postmenopausal women with a femoral neck T-score > -2.5 for alendronate therapy: a modeling study Cost-effectiveness of vertebral fracture assessment to detect prevalent vertebral deformity (...) and select postmenopausal women with a femoral neck T-score > -2.5 for alendronate therapy: a modeling study Schousboe J T, Ensrud K E, Nyman J A, Kane R L, Melton L J Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of vertebral

2006 NHS Economic Evaluation Database.

40. Cost-effectiveness of osteoporosis screening and treatment with hormone replacement therapy raloxifene, or alendronate

Cost-effectiveness of osteoporosis screening and treatment with hormone replacement therapy raloxifene, or alendronate Cost-effectiveness of osteoporosis screening and treatment with hormone replacement therapy raloxifene, or alendronate Cost-effectiveness of osteoporosis screening and treatment with hormone replacement therapy raloxifene, or alendronate Mobley L R, Hoerger T J, Wittenborn J S, Galuska D A, Rao J K Record Status This is a critical abstract of an economic evaluation that meets (...) the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The study examined a strategy of screening women for osteoporosis at age 65 years, and treatment for those who tested positive. The three alternative treatments considered were hormone replacement therapy (HRT), raloxifene and alendronate. All women were screened using

2006 NHS Economic Evaluation Database.